- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06711887
Fase III forlængelsesundersøgelse af Ianalumabs effektivitet og sikkerhed med eller uden undersøgelsesbehandlingsseponering hos deltagere med lupus nefritis (SIRIUS-LN forlængelse) (SIRIUS-LN ext)
Et åbent udvidelsesstudie for at vurdere effektiviteten og sikkerheden af Ianalumab med eller uden tilbagetrækning af undersøgelsesbehandling hos voksne deltagere med lupus nefritis, som har afsluttet undersøgelsesbehandling i CVAY736K12301 Core Study (SIRIUS-LN Extension)
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety
- after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or partial renal response [PRR]) on double-blind treatment at the end of the SIRIUS-LN core study, and
- of open-label ianalumab 300 mg treatment in patients who, at the end of the SIRIUS-LN core study, were either already receiving ianalumab open-label treatment or did not meet CRR/PRR criteria on double-blind treatment at the end of the SIRIUS-LN core study.
Studieoversigt
Detaljeret beskrivelse
The SIRIUS-LN extension study is an up to 6-year open-label extension study for participants who have completed the treatment periods (blinded Treatment Period-1 and blinded Treatment Period-2) of the SIRIUS-LN core study on double-blind or open-label study treatment.
Investigators will use their clinical judgment to decide if it is beneficial for participants to continue with the extension study. In this extension study participants who achieve CRR or PRR status at Week 140 will be withdrawn from study treatment and will maintain the SoC medication as required. These up to 6 additional years in the extension study will allow to measure sustained remission, flares and safety off-study treatment. However, in the event of renal flares during the extension study, these participants who withdraw study treatment will have the option to receive open-label ianalumab.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Udvidet adgang
Kontakter og lokationer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Undersøgelse Kontakt Backup
- Navn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
- E-mail: novartis.email@novartis.com
Studiesteder
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasilien, 29055-450
- Rekruttering
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasilien, 40150-150
- Rekruttering
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasilien, 30150-221
- Rekruttering
- Novartis Investigative Site
-
-
Pernambuco
-
Recife, Pernambuco, Brasilien, 50740-900
- Rekruttering
- Novartis Investigative Site
-
-
São Paulo
-
Santo André, São Paulo, Brasilien, 09090-790
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Rekruttering
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Rekruttering
- Novartis Investigative Site
-
-
-
-
New York
-
Orchard Park, New York, Forenede Stater, 14127
- Rekruttering
- Circuit Clinical
-
Ledende efterforsker:
- Isha Gupta
-
Kontakt:
- Gabriella Demelo
- E-mail: gdemelo@circuitclinical.com
-
-
-
-
-
Grenoble, Frankrig, 38043
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Guatemala City, Guatemala, 01010
- Rekruttering
- Novartis Investigative Site
-
-
Departamento de Guatemala
-
Guatemala City, Departamento de Guatemala, Guatemala, 01011
- Rekruttering
- Novartis Investigative Site
-
-
Departamento de Quetzaltenango
-
Quetzaltenango, Departamento de Quetzaltenango, Guatemala, 09001
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Tuenmen, Hong Kong, 999077
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Beijing, Kina, 100034
- Rekruttering
- Novartis Investigative Site
-
Chongqing, Kina, 400038
- Rekruttering
- Novartis Investigative Site
-
Guangzhou, Kina, 510280
- Rekruttering
- Novartis Investigative Site
-
Guangzhou, Kina, 510080
- Rekruttering
- Novartis Investigative Site
-
Shanghai, Kina, 200080
- Rekruttering
- Novartis Investigative Site
-
Shanghai, Kina, 200040
- Rekruttering
- Novartis Investigative Site
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510000
- Rekruttering
- Novartis Investigative Site
-
Shantou, Guangdong, Kina, 515000
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Shenzhen, Guangdong, Kina, 518037
- Rekruttering
- Novartis Investigative Site
-
-
Guangxi
-
Liuzhou, Guangxi, Kina, 545005
- Rekruttering
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Kina, 430060
- Rekruttering
- Novartis Investigative Site
-
-
Jilin
-
Changchun, Jilin, Kina, 130041
- Rekruttering
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110004
- Rekruttering
- Novartis Investigative Site
-
-
Shandong
-
Binzhou, Shandong, Kina, 256603
- Rekruttering
- Novartis Investigative Site
-
-
Zhejiang
-
Ningbo, Zhejiang, Kina, 315016
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malaysia, 50586
- Rekruttering
- Novartis Investigative Site
-
-
Sarawak
-
Sibu, Sarawak, Malaysia, 96000
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City, Mexico, 68020
- Rekruttering
- Novartis Investigative Site
-
Querétaro, Mexico, 76070
- Rekruttering
- Novartis Investigative Site
-
-
Guanajuato
-
León, Guanajuato, Mexico, 37160
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bucharest, Rumænien, 022328
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 169608
- Rekruttering
- Novartis Investigative Site
-
-
Singapore
-
Singapore, Singapore, Singapore, 308433
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Seoul, Sydkorea, 06591
- Rekruttering
- Novartis Investigative Site
-
Seoul, Sydkorea, 03722
- Rekruttering
- Novartis Investigative Site
-
Seoul, Sydkorea, 04763
- Rekruttering
- Novartis Investigative Site
-
-
Gyeonggi-do
-
Suwon, Gyeonggi-do, Sydkorea, 16499
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Taichung, Taiwan, 40447
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thailand, 10400
- Rekruttering
- Novartis Investigative Site
-
Bangkok, Thailand, 10330
- Rekruttering
- Novartis Investigative Site
-
Bangkok, Thailand, 10700
- Rekruttering
- Novartis Investigative Site
-
Chiang Mai, Thailand, 50200
- Rekruttering
- Novartis Investigative Site
-
-
Hat Yai
-
Songkhla, Hat Yai, Thailand, 90110
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Olomouc, Tjekkiet, 779 00
- Aktiv, ikke rekrutterende
- Novartis Investigative Site
-
Prague, Tjekkiet, 128 00
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Budapest, Ungarn, 1097
- Rekruttering
- Novartis Investigative Site
-
-
-
-
VNM
-
Ho Chi Minh City, VNM, Vietnam, 700000
- Rekruttering
- Novartis Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Signed informed consent prior to participation in the extension study.
- Participants must have participated in the SIRIUS-LN core study and must have completed the entire treatment up to Week 144 on double-blind or open label study treatment.
Exclusion Criteria:
- Use of prohibited therapies
- Pregnant or nursing (lactating) women.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Study Treatment Withdrawal (cohort 1)
(Cohort 1): Study Treatment-Withdrawal group. Participants who received blinded study treatment in the core study and achieve CRR or PRR at Week 140 in the core study will enter the extension study and discontinue study treatment while maintaining standard of care (SoC) medication, as required. If renal flare criteria are met, participants will be eligible to receive open-label ianalumab. |
|
|
Eksperimentel: Open-Label Ianalumab (cohort 2)
(Cohort 2): Open-Label Ianalumab group: Participants who received blinded study treatment throughout the core study and did not achieve CRR or PRR at Week 140 of the core study, or who had switched to open-label ianalumab during the core study, will be eligible or will continue to receive open-label ianalumab in the extension study. |
Ianalumab (VAY736) is a human monoclonal antibody (mAb) of the IgG1/κ-class, directed against B cells and binding to BAFF receptor (BAFF-R).
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cohort 1: Time to renal flare, increase in immunosuppressive medication, or death
Tidsramme: Between Week 144E1 and EOS (up to Week 456)
|
Cohort 1: To estimate the time to renal flare, increase in immunosuppressive medication, or death following study treatment withdrawal in participants who completed the SIRIUS-LN core study on double-blind treatment and achieved CRR or PRR at Week 140 of the core study |
Between Week 144E1 and EOS (up to Week 456)
|
|
Cohort 2: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cohort 2: Incidence and titer of anti-ianalumab antibodies in serum (ADA assay)
Tidsramme: from Week 144E1 up to Week 456
|
To assess immunogenicity to ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 2: Ianalumab concentration in serum using a validated ELISA
Tidsramme: from Week 144E1 up to Week 456
|
To assess pharmacokinetics of ianalumab in Cohort 2 |
from Week 144E1 up to Week 456
|
|
Cohort 1: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Number of participants with AEs and SAEs, including changes in vital signs and clinical laboratory measurements qualifying and reported as AEs. |
From the start of treatment in the SIRIUS-LN core study to EOS (up to week 560) of the extension study
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Bindevævssygdomme
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Glomerulonefritis
- Lupus erythematosus, systemisk
- Nefritis
- Hud- og bindevævssygdomme
- Lupus nefritis
- Ianalumab
Andre undersøgelses-id-numre
- CVAY736K12301E1
- 2024-515280-60-00 (Anden identifikator: EU CTR)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .